The top Canonical Pathways affected by SCLC treatment were Molecular Mechanisms of Cancer, Glioblastoma Multiforme Signaling, Glioblastoma Signaling, PI3K/AKT Signaling, and Glucocorticoid Receptor Signaling. This evidence concerns the gene NR3C1 and small cell lung carcinoma.